Literature DB >> 2248123

The development of a Short Opiate Withdrawal Scale (SOWS).

M Gossop1.   

Abstract

In previous studies a 32-item Opiate Withdrawal Scale was found to provide a reliable and valid means of measuring the signs and symptoms of withdrawal among heroin (and other opiate) addicts. This paper describes the processes whereby a shorter 10-item version of the same scale was developed. The Short Opiate Withdrawal Scale (SOWS) is simple to understand and easy to administer, and it avoids the redundancy of items contained in the original scale. It is suggested that the SOWS provide a useful instrument which can be used both in research and clinical practice with opiate addicts.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2248123     DOI： 10.1016/0306-4603(90)90036-w

Source DB:  PubMed          Journal:  Addict Behav        ISSN： 0306-4603            Impact factor:   3.913


  45 in total

1.  Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes.

Authors:  Carlton D Dampier; Wally R Smith; Hae-Young Kim; Carrie Greene Wager; Margaret C Bell; Caterina P Minniti; Jeffrey Keefer; Lewis Hsu; Lakshmanan Krishnamurti; A Kyle Mack; Donna McClish; Sonja M McKinlay; Scott T Miller; Ifeyinwa Osunkwo; Phillip Seaman; Marilyn J Telen; Debra L Weiner
Journal:  Am J Hematol       Date:  2011-09-22       Impact factor: 10.047

2.  Increased local and decreased remote functional connectivity at EEG alpha and beta frequency bands in opioid-dependent patients.

Authors:  Andrew A Fingelkurts; Alexander A Fingelkurts; Reetta Kivisaari; Taina Autti; Sergei Borisov; Varpu Puuskari; Olga Jokela; Seppo Kähkönen
Journal:  Psychopharmacology (Berl)       Date:  2006-07-19       Impact factor: 4.530

Review 3.  Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

4.  Reliability and Validity Study of the Turkish Version of the Clinical Opiate Withdrawal Scale.

Authors:  A Ender Altintoprak; E Cüneyt Evren; Ömer Aydemir; Aslıhan Yapici Eslek; Yeşim Can; Elif Mutlu; Levent Tokuçoğlu; Artuner Deveci; Hakan Coşkunol
Journal:  Noro Psikiyatr Ars       Date:  2015-03-01       Impact factor: 1.339

5.  Sleep disturbances and pain among individuals with prescription opioid dependence.

Authors:  Emily E Hartwell; James G Pfeifer; Jenna L McCauley; Megan Moran-Santa Maria; Sudie E Back
Journal:  Addict Behav       Date:  2014-06-02       Impact factor: 3.913

6.  Using Acceptance and Commitment Therapy during Methadone Dose Reduction: Rationale, Treatment Description, and a Case Report.

Authors:  Angela L Stotts; Akihiko Masuda; Kelly Wilson
Journal:  Cogn Behav Pract       Date:  2009-05-01

7.  No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.

Authors:  Matthew P Kosloski; Weihan Zhao; Armen Asatryan; Jens Kort; Pierre Geoffroy; Wei Liu
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

8.  Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.

Authors:  Diane Warden; Geetha A Subramaniam; Thomas Carmody; George E Woody; Abu Minhajuddin; Sabrina A Poole; Jennifer Potter; Marc Fishman; Michael Bogenschutz; Ashwin Patkar; Madhukar H Trivedi
Journal:  Addict Behav       Date:  2012-05-08       Impact factor: 3.913

9.  Scopolamine detoxification technique for heroin dependence: a randomized trial.

Authors:  Sheng Liu; Longhui Li; Wenwen Shen; Xueyong Shen; Guodong Yang; Wenhua Zhou
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 10.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.